Navigation Links
Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds
Date:2/19/2014

the drug as a frontline therapy -- even with virtually no data to support that decision. It was important from a patient care and regulatory standpoint that we conduct this trial."

The Phase III, international study (RTOG 0825) was a collaboration of three cooperative groups: RTOG, NCCTG and ECOG. The randomized, double-blind, placebo-controlled study registered 978 and enrolled 637 patients, respectively, all of whom were newly diagnosed with glioblastoma.

Participants underwent surgery to resect some or most of the tumor, received the standard of care of chemoradiation with temozolomide, and were randomized to receive either bevacizumab or placebo. The study was designed with two primary endpoints: PFS and overall survival OS.

Two distinguishing factors of the study design include: crossover to bevacizumab in the placebo arm at the time of progression, and longitudinal assessment of symptom burden, neurocognitive function and quality of life.

"With the crossover, we could determine the possible overall, or progression-free survival benefits that could distinguish the potential benefits of early versus later use of bevacizumab," Gilbert said. "Also, there may be some alternative advantages for delaying progression in the disease. In order to interpret that possible delay in progression, it was important to understand what the quality of the survival of that possible progression free survival interval."

A third distinction: the study was designed to look at the impact of pre-specified molecular markers -- a nine-gene signature expression and MGMT methylation -- to determine if a subgroup that specifically benefited from bevacizumab could be identified.

The researchers found no difference in OS between the bevacizumab and placebo arms, 15.7 and 16.1 months, respectively. PFS did not reach the pre-set level statistical significance -- although longer in those taking bevacizumab upfront (10.7 months), compared to i
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Bevacizumab (Avastin) fails to improve survival for newly diagnosed glioblastoma patients
2. Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer promising
3. Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
4. Brain cancer survival improved following FDA approval of bevacizumab, Mayo study finds
5. Test helps target glioblastoma patients most likely to benefit from bevacizumab
6. Bevacizumab offers no benefit for newly diagnosed glioblastoma, M.D. Anderson-led study finds
7. Study finds glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life
8. Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
9. Innovating for the Global South: New book offers practical insights
10. Fruit fly microRNA research at Rutgers-Camden offers clues to aging process
11. NIH study offers insight into why cancer incidence increases with age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Washington, DC (PRWEB) April 26, 2015 ... for Seniors (ACE.S) , a national endeavor to prepare ... older adults, is a great success, according to a ... of the program's original funding partners. , The ... College of Philadelphia (CCP), under the direction of Elaine ...
(Date:4/25/2015)... 2015 Diversified Communications has announced ... event. The Integrative Healthcare Symposium Canada, as it’s ... at the Sheraton Parkway Toronto North in Ontario. ... of the most anticipated events of the year ... program. The event aims to gather multi-disciplined practitioners ...
(Date:4/25/2015)... 26, 2015 Avid Collector Andrew Hawley ... Rolling Stones Greensboro Coliseum concert posters. The concert was ... the Stone's Second American Tour. , According to ... out of Baltimore, Maryland. This poster blank was used ... southern cites. Globe uses garish lettering and colors on ...
(Date:4/25/2015)... D.C. (PRWEB) April 25, 2015 In ... worldwide will join The Million Nets Pledge, a two-year ... campaign to protect refugee families with one million bednets ... their increased work with UN partners to protect children, ... from malaria. , “There has been a large ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of the ... following the deadly earthquake in Nepal: , "Today a ... deaths of more than 1,000 people. The aftershocks ... India and other parts of South Asia. I ... of Nepal and the families of the victims. ...
Breaking Medicine News(10 mins):Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:Integrative Healthcare Event launching in Canada 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4
... be as effective as a second medication for as ... not been cured by a single antidepressant medication. ... recently published in the Journal of Clinical Psychiatry, found ... can work as well as administering a second antidepressant ...
... , TUESDAY, Aug. 23 (HealthDay News) -- Accidental ... cancer nurses in the United States, a new study ... state who work in outpatient chemotherapy infusion centers and ... eyes had been exposed to the drugs. In ...
... -- Researchers say boys are becoming physically mature earlier ... reaching sexual maturity about 2.5 months earlier every decade ... reason for earlier maturity for boys, as with girls, ... more favorable for it," demographer Joshua Goldstein, director of ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, ... research investigating injectable drugs to treat psoriasis -- an ... the medications are not linked to higher heart risks. ... complete information from drug makers impeded their ability to ...
... than 1 million patients in North America, results from ... as bacteria, in people genetically predisposed to the disorder. ... colon, is one such condition. The aberrant immune ... small signaling proteins secreted by various cells, including ...
... TUESDAY, Aug. 23 (HealthDay News) -- A test that detects ... likely to raise the risk of invasive cervical cancer, when ... many women than the Pap test alone, a new study ... the HPV test alone appears to be enough, said study ...
Cached Medicine News:Health News:Exercise can substitute effectively as second 'medication' for people with depression 2Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3
(Date:4/25/2015)... Hospira, Inc. (NYSE: ... Biosimilar-Behandlungen, sprach heute auf der jährlichen Konferenz der ... London über die Bedeutung ... Biosimilars für Patienten. Das Unternehmen kündigte ... dem Titel „Why extrapolation is paramount to ...
(Date:4/25/2015)... 2015  With the introduction of Elekta,s new Leksell ... are now available for more patients with a wider ... stereotactic radiosurgery system for the brain, integrates advanced motion ... versatility of Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma ... Forum in Barcelona . ...
(Date:4/24/2015)... Hampshire , und BARCELONA ... -- (Stand Nr. 4410) iCAD, Inc. (Nasdaq: ... von moderner Bildanalyse, Lösungen für Behandlungsabläufe und ... Krebserkrankungen, hat heute die sofortige Verfügbarkeit des ... Electronic Brachytherapy (eBx ® ) System ® ...
Breaking Medicine Technology:Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 2Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 4Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 5Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 6
... CITY, Calif., Jan. 6, 2012  myoscience, Inc. of Redwood ... Robert E. Grant as Chairman of the Board of ... Chief Executive Officer and President of Bausch & Lomb ... Allergan.  Mr. Grant has been a board member for ...
... USHIFU, LLC (US HIFU), a world leader in minimally ... Klein as the company,s new chief executive officer and ... more than 30 years of experience in oncology and ... as president of the radiation oncology division of Roper ...
Cached Medicine Technology:myoscience Announces Robert Grant as Chairman of the Board 2US HIFU Names New Chief Executive Officer 2US HIFU Names New Chief Executive Officer 3
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
... Trio with Tim™ (Total imaging matrix) ... speed, and highest resolution at 3T. ... 16, advanced applications can now be ... Trio with Tim is an excellent ...
... scan every beating heart at any heart rate ... A scanner using two X-ray sources and two ... diagnosis in acute care; even with large patients, ... the Cardiac Engine, a unique combination of Siemens ...
Medicine Products: